Helius Medical Technologies calls the out-of-network reimbursement the first step in making the PoNS device more accessible to MS patients.

Helius Medical Technologies, Inc. (Nasdaq: HSDT) announced that Aetna Healthcare has authorized a claim for reimbursement for ...

Helius Medical Technologies (NASDAQ:HSDT) shares are trading higher Wednesday after the company announced an authorized claim ...

Helius President and CEO Dane Andreeff expressed optimism about the company’s strategy to increase patient access to PoNS, stating that the recent reimbursement approval will aid in supporting more MS ...

announced today that United Healthcare has approved reimbursement for the Portable Neuromodulation Stimulator (PoNS) device for patients with multiple sclerosis (MS). This marks the second major ...

United Healthcare approves claim for PoNS Device at out ... and broad third-party reimbursement as part of our growth strategy to increase patient access to PoNS. We are pleased with this progress in ...

The device is an investigational device in most markets, currently only available for sale in the US. The TPT program provides a clear reimbursement pathway for medical systems like EBR’s WISE ...

for its PoNS Device. “The first reimbursement from a commercial healthcare provider is a significant achievement for Helius and MS patients. The payment at out-of-network adjusted list price further ...